SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models

Expression of the Met/HGF receptor in normal and neoplastic human tissues.

Maria Flavia Di Renzo, Radha P. Narsimhan, Martina Olivero et al. · PubMed · 1991 · 479 citations

Medicine, Oncology, Pathology +14

MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

Renhui Yang, Zhong Zheng, Mally Romero et al. · Cancer Research · 2008 · 208 citations

Medicine, Cancer Biology, Oncology +13

AMG 102, A Fully Human Anti-Hepatocyte Growth Factor/Scatter Factor Neutralizing Antibody, Enhances the Efficacy of Temozolomide or Docetaxel in U-87 MG Cells and Xenografts

H. Toni Jun, Jan Sun, Karen Rex et al. · Clinical Cancer Research · 2007 · 145 citations

Medicine, Oncology, Pharmacology +15

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer

J.F. Liu, Kathleen N. Moore, Michael J. Birrer et al. · Annals of Oncology · 2016 · 140 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +12

ABBV-399, a c-Met Antibody–Drug Conjugate that Targets Both <i>MET</i> –Amplified and c-Met–Overexpressing Tumors, Irrespective of <i>MET</i> Pathway Dependence

Jieyi Wang, Mark G. Anderson, Anatol Oleksijew et al. · Clinical Cancer Research · 2016 · 140 citations · Full text

Medicine, Oncology, Pharmacology +16